Citation Impact
Citing Papers
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
1989 Standout
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1
2005
The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy
2012
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex
2000
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
2008
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
1998 Standout
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma
2004
Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the princess margaret hospital experience
1991
Nasopharyngeal carcinoma
2019 Standout
Nanocarriers for delivery of platinum anticancer drugs
2013
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
2008
Molecular mechanisms of cisplatin resistance
2011 Standout
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Targeting Anticancer Drugs to the Brain. I: Enhanced Brain Delivery of Oxantrazole following Administration in Magnetic Cationic Microspheres
1993
A review of PARP inhibitors: from bench to bedside
2010
Carboplatin: current status and future prospects
1988
Analysis of anticancer drugs: A review
2011 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods
2002 Standout
NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699
2011
Cisplatin: The first metal based anticancer drug
2019 Standout
Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability
2016 StandoutNobel
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Catalytic CC, CN, and CO Ullmann‐Type Coupling Reactions
2009 Standout
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Organic Azides: An Exploding Diversity of a Unique Class of Compounds
2005 Standout
New Developments and Approaches in the Platinum Arena
2000
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Chitosan microspheres as a potential carrier for drugs
2004 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
1997 Standout
Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis
2016 Standout
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4
2005
Synthesis and Porous Properties of Chromium Azolate Porous Coordination Polymers
2014 StandoutNobel
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
2007
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
γ‐Peptides Forming More Stable Secondary Structures than α‐Peptides: Synthesis and helical NMR‐solution structure of the γ‐hexapeptide analog of H‐(Val‐Ala‐Leu)2‐OH
1998
Diazaquinomycin A, a new antifolate antibiotic, inhibits thymidylate synthase.
1985 StandoutNobel
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
2002
β-Peptides: From Structure to Function
2001 Standout
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
2012 Standout
Small-Molecule H-Bond Donors in Asymmetric Catalysis
2007 Standout
Chlorambucil-Adducts in DNA Analyzed at the Oligonucleotide Level Using HPLC-ESI MS
2009
Optimizing drug delivery to brain tumors
1987
The Chemistry of Neutron Capture Therapy
1998 Standout
A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice
1981
N2-Substituted O6-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2
2004
The selectivity of protein kinase inhibitors: a further update
2007 Standout
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
2014 Standout
Design and Synthesis of Potent Non-Polyglutamatable Quinazoline Antifolate Thymidylate Synthase Inhibitors
1999
Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
2011
The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks
2005
A novel and efficient methodology for the construction of quinazolines based on supported copper oxide nanoparticles
2010
Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
2005
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
2015 Standout
Drug Level Monitoring: Cytostatics
1985
5‐Substituted 1H‐Tetrazoles as Carboxylic Acid Isosteres: Medicinal Chemistry and Synthetic Methods
2003 Standout
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Optimization of the Conditions for Copper‐Mediated N‐Arylation of Heteroarylamines
2007
Works of AH Calvert being referenced
A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors
1999
Kinetically-based multiple drug treatment for advanced head and neck cancer.
1975
Quinazoline Antifolate Thymidylate Synthase Inhibitors: Replacement of Glutamic Acid in the C2-Methyl Series
1995
Syntheses and thymidylate synthase inhibitory activity of the poly-.gamma.-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates
1992
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors
2005
Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors
2006
Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies
1999
Studies on the pharmacokinetics of chlorambucil and prednimustine in man.
1983
Structure-Based design of 2-Arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-Dependent kinases 1 and 2
2003
A PHASE-I HIGH-DOSE ESCALATION STUDY OF CARBOPLATIN
1987
2-AMINO-4-HYDROXY QUINAZOLINES WITH DUAL METABOLIC LOCI IN METHOTREXATE RESISTANT CELLS
1979